文献速递消化道肿瘤放疗放疗物理与技术

局部进展或复发胰腺癌剂量递增SIB光子或质子放疗的模拟研究:胃肠道器官仍是关键限制

Dose-escalated simultaneously integrated boost photon or proton therapy in pancreatic cancer in an in-silico study: Gastrointestinal organs remain critical.
PubMed 文献 · Clin Transl Radiat Oncol · 2020-12-09

该模拟研究对15例局部进展胰腺癌患者比较VMAT、Tomotherapy和IMPT三种技术在大分割SIB剂量递增方案下的剂量学结果,处方为GTV 66 Gy/30次、PTV或CTV 51 Gy/30次。所有技术均达到靶区处方剂量,但胃、十二指肠和小肠常受到超过50 Gy的照射;在低于50 Gy的剂量区域,IMPT在降低危及器官受量方面显著优于两种光子技术。结论是无论使用何种技术,胃肠道危及器官的剂量限制仍是剂量递增SIB方案的关键问题。

要点

  • 15例局部进展胰腺癌模拟计划中,三种技术均达到GTV 66 Gy和PTV/CTV 51 Gy的处方剂量。
  • 胃、十二指肠和小肠常受到超过50 Gy的照射,各技术间无差异。
  • 低于50 Gy区域IMPT优于光子技术,如肠V15Gy较VMAT和TOMO显著降低。

核心结论

  • 在不可切除局部复发或进展胰腺癌的剂量递增SIB方案中,所有光子和质子技术的胃肠道危及器官受量均仍是关键限制。

研究设计与样本

  • 模拟研究纳入15例局部进展胰腺癌患者,在自由呼吸CT上分别优化VMAT、Tomotherapy和IMPT计划。
  • 光子计划处方为GTV 66 Gy、PTV 51 Gy,均30次SIB;质子计划处方为GTV 66 Gy(RBE)、CTV 51 Gy(RBE)。
  • 对每例SIB计划评估靶区和危及器官剂量并进行统计学比较。

主要发现

  • 所有技术均达到GTV和CTV或PTV的处方剂量。
  • 胃、十二指肠和小肠常受到超过50 Gy的照射,与治疗技术无关。
  • 对于低于50 Gy的剂量,IMPT在降低危及器官受量方面显著优于两种光子技术。
  • 肠V15Gy在IMPT较VMAT降低(p=0.003),较TOMO降低(p<0.001)。

关键数值与推荐

  • 光子计划处方:GTV 66 Gy、PTV 51 Gy,30次SIB。
  • 质子计划处方:GTV 66 Gy(RBE)、CTV 51 Gy(RBE)。
  • IMPT较VMAT肠V15Gy降低的p=0.003,较TOMO降低的p<0.001。

临床怎么用

  • 剂量递增SIB方案设计时需重点评估胃、十二指肠和小肠的受量。
  • 质子技术可能降低低于50 Gy区域的胃肠道危及器官剂量,但高剂量区限制仍存在。

局限性

  • 为模拟剂量学研究,非临床结局研究。
  • 样本量为15例局部进展胰腺癌患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare the dosimetric results of an in-silico study among intensity-modulated photon (IMRT) and robustly optimized intensity-modulated proton (IMPT) treatment techniques using a dose-escalated simultaneously integrated boost (SIB) approach in locally recurrent or advanced pancreatic cancer patients. MATERIAL AND METHODS: For each of 15 locally advanced pancreatic cancer patients, a volumetric-modulated arc therapy (VMAT), a Tomotherapy (TOMO), and an IMPT treatment plan was optimized on free-breathing treatment planning computed tomography (CT) images. For the photon treatment plans, doses of 66 Gy and 51 Gy, both as SIB in 30 fractions, were prescribed to the gross tumor volume (GTV) and to the planning target volume (PTV), respectively. For the proton plans, a dose prescription of 66 Gy(RBE) to the GTV and of 51 Gy(RBE) to the clinical target volume (CTV) was planned. For each SIB-treatment plan, doses to the targets and OARs were evaluated and statistically compared. RESULTS: All treatment techniques reached the prescribed doses to the GTV and CTV or PTV. The stomach and the bowel, in particular the duodenum and the small bowel, were found to be frequently exposed to doses exceeding 50 Gy, irrespective of the treatment technique. For doses below 50 Gy, the IMPT technique was statistically significant superior to both IMRT techniques regarding decreasing dose to the OARs, e.g. volume of the bowel receiving 15 Gy (V 15Gy) was reduced for IMPT compared to VMAT (p = 0.003) and TOMO (p < 0.001). CONCLUSION: With all photon and proton techniques investigated, the radiation dose to gastrointestinal OARs remained critical when treating patients with unresectable locally recurrent or advanced pancreatic cancer using a dose-escalated SIB approach.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Stefanowicz S, Wlodarczyk W, Frosch S, et al. Dose-escalated simultaneously integrated boost photon or proton therapy in pancreatic cancer in an in-silico study: Gastrointestinal organs remain critical. Clin Transl Radiat Oncol. 2020. PMID: 33392399. doi:10.1016/j.ctro.2020.12.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。